Tobias Freitag, MD, is a medical researcher and experimental immunologist, trained in clinical gastroenterology and rheumatology. His scientific research is focused on mucosal immunology and translational medicine, autoimmune diseases, particularly celiac disease, mechanisms of tolerance to intestinal antigens (food, microbial and self-proteins), regulatory T cell function and rodent disease models. He has been a principal investigator of the Finnish-Swedish NARPANord consortium, investigating pathogenesis of type 1 narcolepsy, and is currently a participant in an Academy of Finland COVID19 research consortium, studying cellular immunity to SARS-CoV-2. Starting from 2019, he has contributed as Junior Researcher to the Translational Immunology Research Program at the University of Helsinki, investigating therapeutic immune tolerance induction in autoimmune diseases.